Clinical trial · Interventional
Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
Efficacy of Telmisartan in Preventing Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients
NCT07370506CI-TRIAL-00101945not yet recruitingPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to evaluate the efficacy and safety of telmisartan as a cardioprotective agent in patients receiving doxorubicin-based chemotherapy, with the goal of reducing treatment-associated cardiotoxicity, optimizing therapeutic outcomes, and facilitating the safer administration of anthracycline regimens.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Doxorubicin Induced Cardiomyopathy | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Doxorubicin (DOX) | Drug | Doxorubicin | ALIAS |
| Telmisartan | Drug | Telmisartan | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Telmisartan Group
- description
- Participants receiving telmisartan in addition to standard doxorubicin-based chemotherapy.
- interventionNames
- Drug: Telmisartan
- Drug: Doxorubicin (DOX)
- type
- ACTIVE_COMPARATOR
- label
- Control Group
- description
- Participants receiving standard doxorubicin-based chemotherapy without telmisartan.
- interventionNames
- Drug: Doxorubicin (DOX)
Primary outcomes (1)
- measure
- Change in Left Ventricular Ejection Fraction (LVEF)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Female patients with breast cancer. * Age ≥18 \& ≤ 65 years. * Newly diagnosed, chemotherapy-naïve patients. * Baseline echocardiogram showing left ventricular ejection fraction (LVEF) ≥55%. Exclusion Criteria: * Presence of hypersensitivity to telmisartan. * History of cardiovascular disease (e.g., congestive heart failure, ischemic heart disease, arrhythmia). * Patients with any chronic liver or renal dysfunction; inflammatory diseases; autoimmune disease; acute cardiovascular events, eating disorders (anorexia, bulimia) or gastrointestinal disorders. * Baseline blood pressure ≥ 160/100 mmHg * Current or prior use of ARBs/ACE inhibitors * Current participation in another clinical trial within the past 30 days. * Pregnant or breastfeeding women.
References
Publications (5)
- BACKGROUNDSeino Y, Takahashi H, Fukumoto H, Utsumi K, Hirai Y. Cardiovascular manifestations of Fabry disease and the novel therapeutic strategies. J Nippon Med Sch. 2005 Oct;72(5):254-61. doi: 10.1272/jnms.72.254. PMID 16247224
- BACKGROUNDTaniguchi N. From the gamma-glutamyl cycle to the glycan cycle: a road with many turns and pleasant surprises. J Biol Chem. 2009 Dec 11;284(50):34469-78. doi: 10.1074/jbc.X109.023150. Epub 2009 Oct 19. No abstract available. PMID 19840938
- BACKGROUNDArciuli J, Simpson IC. Statistical learning is lasting and consistent over time. Neurosci Lett. 2012 May 31;517(2):133-5. doi: 10.1016/j.neulet.2012.04.045. Epub 2012 Apr 25. PMID 22561650
- BACKGROUNDSimeunovic B, Strbenc M, Bavdek SV. Position and histological structure of the testes in the brown hare (Lepus europaeus) during seasonal regression and recrudescence. Anat Histol Embryol. 2000 Apr;29(2):73-82. doi: 10.1046/j.1439-0264.2000.00233.x. PMID 10932383
- BACKGROUNDBanegas JR, Segura J, Ruilope LM, Luque M, Garcia-Robles R, Campo C, Rodriguez-Artalejo F, Tamargo J; CLUE Study Group Investigators. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension. 2004 Jun;43(6):1338-44. doi: 10.1161/01.HYP.0000127424.59774.84. Epub 2004 Apr 26. PMID 15117908